Daratumumab (Anti-CD38) for Treatment of Disseminated Nontuberculous Mycobacteria in a Patient With Anti-Interferon-γ Autoantibodies

Sebastian Ochoa; Li Ding; Samantha Kreuzburg; Jennifer Treat; Steven M Holland; Christa S Zerbe

doi:10.1093/cid/ciaa1086

Daratumumab (Anti-CD38) for Treatment of Disseminated Nontuberculous Mycobacteria in a Patient With Anti-Interferon-γ Autoantibodies

Clin Infect Dis. 2021 Jun 15;72(12):2206-2208. doi: 10.1093/cid/ciaa1086.

Authors

Sebastian Ochoa¹, Li Ding¹, Samantha Kreuzburg¹, Jennifer Treat², Steven M Holland¹, Christa S Zerbe¹

Affiliations

¹ Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
² Medical Science and Computing, Rockville, Maryland, USA.

Abstract

Patients with autoantibodies to interferon-γ (IFN-γ) may develop severe nontuberculous mycobacterial infections. We describe the novel use of daratumumab in a patient with autoantibodies to IFN-γ who had progressive infection, resulting in clinical and radiographic improvement.

Keywords: autoantibodies; daratumumab; disseminated; interferon gamma; mycobacteria.

Published by Oxford University Press for the Infectious Diseases Society of America 2020.

Publication types

Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural

MeSH terms

Antibodies, Monoclonal / therapeutic use
Autoantibodies
Humans
Interferon-gamma
Mycobacterium Infections, Nontuberculous* / drug therapy
Nontuberculous Mycobacteria*

Substances

Antibodies, Monoclonal
Autoantibodies
daratumumab
Interferon-gamma